Introduction: Several therapeutic options are
INTRODUCTION
The treatment of vitiligo is not well codified and often results are stressful and unsatisfying. A wide range of therapeutic options have been proposed including topical corticosteroids, ultraviolet radiations, either psoralens with ultraviolet A (PUVA) or narrowband-ultraviolet B (NB-UVB), lasers, surgical treatments, and more recently topical calcineurin inhibitors [1] [2] [3] . However, no treatment provides truly satisfactory results.
NB-UVB phototherapy is considered a firstline treatment for extensive vitiligo because of the relatively good efficacy and the excellent tolerance [4] . On the other hand, the topical steroids are indicated for the therapy of limited areas of vitiligo [5] . Clobetasol propionate is the most powerful of these drugs and it is available effect on quality of life [6] . The cutaneous and systemic adverse effects of topical steroids depend on several factors including the activity, the systemic absorption and the bioavailability of the drug, the dose and the duration of the treatment. Clobetasol propionate cream or ointment has already been reported in the therapy of vitiligo [7] [8] [9] , but no data are available regarding the use of foam formulation.
The aim of this study was to investigate the efficacy and tolerability of CPF in the treatment of vitiligo, in comparison with NB-UVB phototherapy.
METHODS

Study Design
The study subjects were selected from a group of adult patients with vitiligo vulgaris who were referred consecutively to the Departments application. When one cup of foam was not sufficient to cover all the lesions, for safety reasons, the patients were suggested to treat only the anatomical site they considered the most disturbing from an esthetic and psychological point of view. Face and intertriginous areas were excluded from the treatment and patients were also asked to stop the treatment in case of occurrence of side effects such as infection signs, atrophy, teleangectasy, and folliculitis. All patients were also asked to avoid the direct UV exposition during the whole period of study and were advised to apply a very high protection sunscreen with frequent reapplication and incorporation of sun avoidance techniques (avoidance of midday sun and wearing a hat).
Clinical Evaluation
The digital lesional photographs, both with Data about potential repigmentation due to NB-UVB of face and intertriginous areas were not reported because in the CPF group those anatomic sites have not been treated since the risk of severe side effects linked to the twicedaily application of a superpotent steroid. During the whole period of the study, any possible side effects were recorded.
Statistical Analysis
Characteristics of the study population are described using mean and standard deviation or median and range for continuous or ordinal 
RESULTS
Patient Characteristics
Baseline characteristics of the study population are summarized in Table 1 . The mean age of the patients treated with CPF was slightly lower compared with those who had received NB-UVB. There was no significant difference in the distribution of sex, pattern, Fitzpatrick's skin phototypes, and family history of vitiligo between the NB-UVB treated group and the CPF-treated group. The duration of vitiligo was significantly shorter in the NB-UVB group compared with the CPF group. Among the comorbidities, thyroid diseases were more frequent in the CPF-treated group.
Comparison Between NB-UVB and CPF Treatments
The results of NB-UVB and CPF treatments in patients with vitiligo are summarized in Table 2 .
The number of patients treated for each anatomic site was homogeneous between the two groups. Overall, for each site, the efficacy of CPF was significantly higher compared with NB-UVB (Fig. 1) . In the CPF-treated group, a variable repigmentation was found, from poor to excellent, at neck, upper and lower limbs, trunk, and hand/wrists (Fig. 2) . Lack of repigmentation was observed at feet/ankles in 6 of 11 treated patients. In the NB-UVB group at feet/ankles, no sign of repigmentation was found in any of the 12 treated patients. In addition, lack of repigmentation was observed at hands/wrists in 13 of 16 treated patients. In the remaining anatomical sites, variable levels of repigmentation were recorded. In the NB-UVB group, none of the patients reported adverse effects throughout the study period. In the CPF group, a woman stopped treatment due to the appearance of diffuse edema. wrists and feet/ankles, despite that both groups showed low repigmentation levels, the median scores were significantly higher in patients treated with CPF. The location of lesions is the most important factor in predicting the response of vitiligo to therapy and previous studies had already shown that face and neck achieve better repigmentation than trunk and extremities [16, 25, 26] . Another factor that may contribute to a good response is the shorter duration of disease [25] . Interestingly, in this study the topical steroid therapy showed a better clinical response, although the duration of disease in the CPF group was significantly longer as compared to the NB-UVB group. This finding seems to confirm the good efficacy of the new topical formulation of this superpotent corticosteroid in patients with vitiligo.
The chronic use of topical corticosteroids might cause side effect as skin atrophy, striae, hypertrichosis, acneiform eruption, and telangiectasia which are limiting factors in vitiligo treatment [27] . CPF has been proposed for long-term therapy in chronic dermatosis [19] [20] [21] [22] [23] . Lacarrubba et al. [28] evaluated through ultrasound imaging the atrophogenic [24] . In the present study, the patients applied CPF twice a day for 5 days/week for 12 weeks.
This therapeutic protocol has already been proposed in alopecia areata by Tosti et al. [22] who demonstrated the safety of this scheme. Overall in this study the adverse effects were It is an established fact that combination of NB-UVB with topical treatment(s) is superior over monotherapy [29] ; therefore, further studies would be opportune to evaluate not only the relative efficiency of and patient's compliance to CPF against traditional clobetasol propionate formulations alone, but also when combined with NB-UVB.
BULLET POINTS
• Recently a new topic formulation of 0.05% clobetasol propionate in thermophobic foam (CPF) has been reported as an effective treatment in several dermatoses, but no data are reported in vitiligo.
• Based on the results of a retrospective study on 60 vitiligo patients, we discuss the efficacy and tolerability of CPF compared to NB-UVB phototherapy.
• CPF is effective and seems to be superior to NB-UVB phototherapy, with a good safety profile.
• This is the first study that investigates the clinical efficacy of CPF in the treatment of vitiligo.
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